Merck KgAA: UBS cuts TP

(CercleFinance.com) - UBS maintains its buy recommendation on the stock, but is lowering its target price for it to E180 (from E190) following its 2024 results.


This target still represents 27% upside potential for the German chemicals and pharmaceuticals group.

We see the strong Q4 results and positive guidance for 2025 as reassuring investors about the recovery in the life sciences sector and the underlying value, it says.

Merck said it expects net sales of E21.5bn to E22.9bn, with Ebitda of E6.1bn to E6.6bn in 2025.


Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.